CTI BioPharma Corp. (CTIC)
CTI BioPharma Statistics
Share Statistics
CTI BioPharma has 131.88M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 131.88M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 99.89M |
| Failed to Deliver (FTD) Shares | 990.03K |
| FTD / Avg. Volume | 17.49% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -7.57 and the forward PE ratio is null. CTI BioPharma's PEG ratio is 0.26.
| PE Ratio | -7.57 |
| Forward PE | n/a |
| PS Ratio | 12.78 |
| Forward PS | n/a |
| PB Ratio | -39.22 |
| P/FCF Ratio | -6.49 |
| PEG Ratio | 0.26 |
Enterprise Valuation
CTI BioPharma has an Enterprise Value (EV) of 708.85M.
| EV / Sales | 13.14 |
| EV / EBITDA | -8.88 |
| EV / EBIT | -8.73 |
| EV / FCF | -6.68 |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of -2.73.
| Current Ratio | 1.23 |
| Quick Ratio | 1.22 |
| Debt / Equity | -2.73 |
| Debt / EBITDA | -0.63 |
| Debt / FCF | -0.47 |
| Interest Coverage | -6.07 |
Financial Efficiency
Return on Equity is 517.96% and Return on Invested Capital is -257.27%.
| Return on Equity | 517.96% |
| Return on Assets | -72.3% |
| Return on Invested Capital | -257.27% |
| Revenue Per Employee | $424.79K |
| Profits Per Employee | $-716.86K |
| Employee Count | 127 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 4.79 |
Taxes
| Income Tax | -1.95M |
| Effective Tax Rate | 2.1% |
Stock Price Statistics
The stock price has increased by 0.11% in the last 52 weeks. The beta is 0.83, so CTI BioPharma's price volatility has been higher than the market average.
| Beta | 0.83 |
| 52-Week Price Change | 0.11% |
| 50-Day Moving Average | 7.44 |
| 200-Day Moving Average | 5.87 |
| Relative Strength Index (RSI) | 83.62 |
| Average Volume (20 Days) | 5.66M |
Income Statement
In the last 12 months, CTI BioPharma had revenue of 53.95M and earned -91.04M in profits. Earnings per share was -0.79.
| Revenue | 53.95M |
| Gross Profit | 50.43M |
| Operating Income | -79.8M |
| Net Income | -91.04M |
| EBITDA | -79.85M |
| EBIT | -79.85M |
| Earnings Per Share (EPS) | -0.79 |
Balance Sheet
The company has 30.42M in cash and 49.96M in debt, giving a net cash position of -19.54M.
| Cash & Cash Equivalents | 30.42M |
| Total Debt | 49.96M |
| Net Cash | -19.54M |
| Retained Earnings | -2.52B |
| Total Assets | 112.27M |
| Working Capital | 18.23M |
Cash Flow
In the last 12 months, operating cash flow was -81.19M and capital expenditures -25M, giving a free cash flow of -106.19M.
| Operating Cash Flow | -81.19M |
| Capital Expenditures | -25M |
| Free Cash Flow | -106.19M |
| FCF Per Share | -0.93 |
Margins
Gross margin is 93.49%, with operating and profit margins of -147.91% and -168.76%.
| Gross Margin | 93.49% |
| Operating Margin | -147.91% |
| Pretax Margin | -172.37% |
| Profit Margin | -168.76% |
| EBITDA Margin | -148.02% |
| EBIT Margin | -147.91% |
| FCF Margin | -196.85% |
Dividends & Yields
CTIC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13.21% |
| FCF Yield | -15.41% |
Analyst Forecast
Currently there are no analyst rating for CTIC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jan 3, 2017. It was a backward split with a ratio of 1:10.
| Last Split Date | Jan 3, 2017 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -27.06 |
| Piotroski F-Score | 3 |